Cardiff Oncology Inc (NASDAQ:CRDF) — Market Cap & Net Worth
Market Cap & Net Worth: Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ:CRDF) has a market capitalization of $116.90 Million ($116.90 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18594 globally and #4113 in its home market, demonstrating a 2.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiff Oncology Inc's stock price $1.71 by its total outstanding shares 68364979 (68.36 Million). Analyse Cardiff Oncology Inc cash flow conversion to see how efficiently the company converts income to cash.
Cardiff Oncology Inc Market Cap History: 2015 to 2026
Cardiff Oncology Inc's market capitalization history from 2015 to 2026. Data shows change from $26.58 Billion to $116.90 Million (-40.47% CAGR).
Index Memberships
Cardiff Oncology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #525 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1810 of 3165 |
Weight: Cardiff Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cardiff Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiff Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
323.96x
Cardiff Oncology Inc's market cap is 323.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.34 Billion | $381.00K | -$39.20 Million | 27130.67x | N/A |
| 2017 | $1.53 Billion | $505.00K | -$24.91 Million | 3021.60x | N/A |
| 2018 | $217.40 Million | $378.00K | -$16.46 Million | 575.13x | N/A |
| 2019 | $84.77 Million | $244.63K | -$16.41 Million | 346.53x | N/A |
| 2020 | $1.23 Billion | $366.00K | -$19.31 Million | 3360.34x | N/A |
| 2021 | $410.87 Million | $359.00K | -$28.29 Million | 1144.49x | N/A |
| 2022 | $95.71 Million | $386.00K | -$38.70 Million | 247.96x | N/A |
| 2023 | $101.18 Million | $488.00K | -$41.44 Million | 207.34x | N/A |
| 2024 | $296.70 Million | $683.00K | -$45.43 Million | 434.41x | N/A |
| 2025 | $192.11 Million | $593.00K | -$45.88 Million | 323.96x | N/A |
Competitor Companies of CRDF by Market Capitalization
Companies near Cardiff Oncology Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cardiff Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cardiff Oncology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cardiff Oncology Inc's market cap moved from $26.58 Billion to $ 116.90 Million, with a yearly change of -40.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $116.90 Million | -39.15% |
| 2025 | $192.11 Million | -35.25% |
| 2024 | $296.70 Million | +193.24% |
| 2023 | $101.18 Million | +5.71% |
| 2022 | $95.71 Million | -76.71% |
| 2021 | $410.87 Million | -66.59% |
| 2020 | $1.23 Billion | +1350.81% |
| 2019 | $84.77 Million | -61.01% |
| 2018 | $217.40 Million | -85.75% |
| 2017 | $1.53 Billion | -85.24% |
| 2016 | $10.34 Billion | -61.11% |
| 2015 | $26.58 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cardiff Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.90 Million USD |
| MoneyControl | $116.90 Million USD |
| MarketWatch | $116.90 Million USD |
| marketcap.company | $116.90 Million USD |
| Reuters | $116.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more